KRAS and non-small cell lung carcinoma: KRAS somatic mutations are biomarkers of aggressive tumor biology (Graziano et al. 1999; Wood et al. 2016) and are associated with worse survival rates and faster recurrence among NSCLC patients (Mascaux et al. 2005; Gautschi et al. 2007).